| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/17/2023 | 72.41% | Barclays | $12 → $10 | Maintains | Overweight |
| 10/11/2023 | 20.69% | Morgan Stanley | $14 → $7 | Maintains | Equal-Weight |
| 08/01/2023 | 141.38% | Morgan Stanley | $14 → $14 | Reiterates | Equal-Weight → Equal-Weight |
| 07/31/2023 | 141.38% | Morgan Stanley | $14 → $14 | Reiterates | Equal-Weight → Equal-Weight |
| 07/24/2023 | 141.38% | Morgan Stanley | $14 → $14 | Reiterates | Equal-Weight → Equal-Weight |
| 07/21/2023 | 124.14% | Berenberg | → $13 | Initiates Coverage On | → Buy |
| 07/20/2023 | 141.38% | Morgan Stanley | $14 → $14 | Reiterates | Equal-Weight → Equal-Weight |
| 07/17/2023 | 141.38% | Morgan Stanley | $14 → $14 | Reiterates | Equal-Weight → Equal-Weight |
| 06/26/2023 | 141.38% | Morgan Stanley | $14 → $14 | Reiterates | Equal-Weight → Equal-Weight |
| 06/20/2023 | 141.38% | Morgan Stanley | → $14 | Reiterates | → Equal-Weight |
| 06/12/2023 | 141.38% | Morgan Stanley | → $14 | Reiterates | → Equal-Weight |
| 04/10/2023 | 141.38% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 11/16/2022 | 106.9% | Barclays | $40 → $12 | Maintains | Overweight |
| 09/09/2022 | 158.62% | Morgan Stanley | $18 → $15 | Maintains | Equal-Weight |
| 08/24/2022 | 210.34% | Morgan Stanley | $20 → $18 | Maintains | Equal-Weight |
| 06/13/2022 | 244.83% | Morgan Stanley | $21 → $20 | Maintains | Equal-Weight |
| 05/24/2022 | 244.83% | Goldman Sachs | $23 → $20 | Maintains | Buy |
| 04/11/2022 | 262.07% | Morgan Stanley | $20 → $21 | Maintains | Equal-Weight |
| 10/26/2021 | 365.52% | B of A Securities | → $27 | Initiates Coverage On | → Buy |
| 10/26/2021 | 331.03% | Morgan Stanley | → $25 | Initiates Coverage On | → Equal-Weight |
| 10/26/2021 | 417.24% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
What is the target price for Exscientia (EXAI)?
The latest price target for Exscientia (NASDAQ: EXAI) was reported by Barclays on October 17, 2023. The analyst firm set a price target for $10.00 expecting EXAI to rise to within 12 months (a possible 72.41% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Exscientia (EXAI)?
The latest analyst rating for Exscientia (NASDAQ: EXAI) was provided by Barclays, and Exscientia maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Exscientia (EXAI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Exscientia, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Exscientia was filed on October 17, 2023 so you should expect the next rating to be made available sometime around October 17, 2024.
Is the Analyst Rating Exscientia (EXAI) correct?
While ratings are subjective and will change, the latest Exscientia (EXAI) rating was a maintained with a price target of $12.00 to $10.00. The current price Exscientia (EXAI) is trading at is $5.80, which is out of the analyst's predicted range.